Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials

2017 ◽  
Vol 14 (2) ◽  
pp. e81-e87
Author(s):  
Chun-Quan Liu ◽  
Dan Tian ◽  
Ning Wang ◽  
Xian-Pu Meng ◽  
Jian-Dong Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Disease ◽  
Randomized Controlled

scholarly journals Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population

2020 ◽  
Author(s):  
Kazuhiko Nakagawa ◽  
Koichi Matsumura ◽  
Tayler Scory ◽  
Megan S Farris ◽  
Kelly A Larkin-Kaiser ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Small Cell Lung ◽  
First Line ◽  
Randomized Controlled ◽  
Egfr Tkis

Background: Five EGFR-tyrosine kinase inhibitors ( EGFR TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of EGFR TKIs in the Japanese population. Materials & methods: A systematic review identified randomized controlled trials examining the efficacy of first-line EGFR TKIs. A Bayesian network meta-analysis was used to assess these EGFR TKI comparisons for progression-free survival (PFS). Results: A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators. Conclusion: Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.

Sign in / Sign up

Export Citation Format

Share Document